.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has actually filed to debut on the general public market.The Eli Lilly-partnered biotech want to list on the Nasdaq under the sign "BIOA," depending on to files submitted with the Stocks and also Substitution Percentage. The business has not publicly discussed an anticipated financial volume for the offering.The clinical-stage provider proclaims lead prospect azelaprag, an orally delivered tiny particle slated to enter phase 2 testing in combination along with semaglutide-- offered by Novo Nordisk under trademark name Wegovy for weight reduction-- in the first half of following year. Semaglutide is also offered as Ozempic as well as Rybelsus through Novo for diabetes.
Apelin receptor agonist azelaprag is developed to blend properly along with GLP-1 drugs, increasing weight management while keeping muscle mass. The investigational medicine was actually located to become well-tolerated one of 265 individuals throughout 8 period 1 tests, depending on to BioAge.Previously, BioAge got the support of Lilly to operate a test incorporating azelaprag along with the Huge Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetes mellitus as Mounjaro and also Zepbound for fat burning. The companions are presently conducting a phase 2 test of azelaprag and tirzepatide, with topline outcomes anticipated in the 3rd quarter of 2025.The biotech is also preparing a blood insulin level of sensitivity proof-of-concept trial evaluating azelaprag as a monotherapy in the initial half of upcoming year to support prospective evidence expansion. Moreover, the business considers to talk to the FDA for permission in the second one-half of 2025 to release individual screening for an NLRP3 inhibitor targeting metabolic health conditions as well as neuroinflammation.BioAge's foreseed move to the public market complies with a small uptick in planned biotech IPOs coming from Bicara Therapeutics and Zenas Biopharma. Zooming out, the recent IPO landscape is actually a "blended picture," along with top quality business still debuting on the general public markets, just in lessened amounts, depending on to PitchBook.